Clinical Study on treatment of mid-late stage gastric carcinoma by compound Xiansu capsule ( ) combined with chemotherapy) combined with chemotherapy

Baojin Hua; Ai-ping Wang; Wei Hou

doi:10.1007/BF02935098

Your Location：

Home >

Browse articles >

Clinical Study on treatment of mid-late stage gastric carcinoma by compound Xiansu capsule ( ) combined with chemotherapy) combined with chemotherapy

Updated：2021-08-27

- Clinical Study on treatment of mid-late stage gastric carcinoma by compound Xiansu capsule ( ) combined with chemotherapy) combined with chemotherapy
- Chinese Journal of Integrative Medicine Vol. 7, Issue 1, Pages: 12-15(2001)
- Affiliations：
  
  1. Heilongjiang University of TCM,Harbin
  2. Guang’ anmen Hospital of China Academy of TCM,Harbin
  3. Oncology Department of Guang’ anmen Hospital of China Academy of TCM,Beijing
- Author bio：
- Funds：
- DOI：10.1007/BF02935098
  CLC：
- Published：2001，
Scan for full text
Hua, B., Wang, Ap. & Hou, W. Clinical Study on treatment of mid-late stage gastric carcinoma by compound Xiansu capsule () combined with chemotherapy) combined with chemotherapy., CJIM 7, 12–15 (2001). https://doi.org/10.1007/BF02935098

Baojin Hua, Ai-ping Wang, Wei Hou. Clinical Study on treatment of mid-late stage gastric carcinoma by compound Xiansu capsule ( ) combined with chemotherapy) combined with chemotherapy. [J]. Chinese Journal of Integrative Medicine 7(1):12-15(2001)
Hua, B., Wang, Ap. & Hou, W. Clinical Study on treatment of mid-late stage gastric carcinoma by compound Xiansu capsule () combined with chemotherapy) combined with chemotherapy., CJIM 7, 12–15 (2001). https://doi.org/10.1007/BF02935098 DOI：

Baojin Hua, Ai-ping Wang, Wei Hou. Clinical Study on treatment of mid-late stage gastric carcinoma by compound Xiansu capsule ( ) combined with chemotherapy) combined with chemotherapy. [J]. Chinese Journal of Integrative Medicine 7(1):12-15(2001) DOI： 10.1007/BF02935098.

摘要

Objective: To assess the effect and mechanism of compound Xiansu capsule ( )

(XSC) combined with chemotherapy in treating gastric carcinoma of mid-late stage.Methods: Sixty-one patients of the test group were treated by XSC combined with chemotherapy and 30 patients of the control group treated with chemotherapy alone. The effect of treatment and cell mediated immunity of patients were observed.Results: The effective rate of the test group and the control group was 32.8% and 13.3% respectively (P < 0.05)

the toxic reaction occurrence caused by chemotherapy was less in the former than that in the latter group (P < 0.01). The CD8 level of patients in the test group decreased

and CD4/CD8 level was raised obviously

which suggested that XSC had immuno-regulating effect on T-cell.Conclusion: XSC could enhance the efficacy and reduce the toxic and side-effect of chemotherapy. To regulate the cell mediated immunity of patients is possibly its mechanism.

Abstract

Objective: To assess the effect and mechanism of compound Xiansu capsule ( )

the toxic reaction occurrence caused by chemotherapy was less in the former than that in the latter group (P < 0.01). The CD8 level of patients in the test group decreased

and CD4/CD8 level was raised obviously

关键词

compound Xiansu capsulechemotherapyT-lymphocyte subsetGastric Carcinoma

Keywords

compound Xiansu capsulechemotherapyT-lymphocyte subsetGastric Carcinoma

references

National Tumor Prevention and Treatment Office, National Association of Anti-Cancer Co-edited. “Chinese common malignant tumor standard of diagnosis and treatment”, the fourth fascicle, 2nd edition. Beijing: Beijing Medical University and Chinese Union Medical University United Press, 1991:14–50.

Sun Y, Zhou JC, chief edited. Clinical tumor medical handbook. 3rd edition. Beijing: People’s Health Publishing House, 1996:24.

Jiangsu New Medical College, chief edited. Chinese drugs dictionary. Shanghai: Shanghai Science and Technology Press, 1986:34.

Shen ZQ, Sun JX, Huang LX. Astragalus in treating selective immunoglobin A deficiency. New Drug and Clinical 1997;16(4):246.

Ding HZ, Yang LY. Application of Ginseng Astragalus decoction in the hepatic artery ligation and embolization in treating mid-late stage liver cancer. CJITWM 1994;14(suppl): 302.

Berghella AM, Barni S, Robin T, et al. Progression mechanisms in gastric or colon cancer: soluble interleukin-2 (IL-2) receptor, IL-2 plus anti-CD3 proliferative response and tumor stage correlation. Cancer Immunol 1994; 38(3):160.

Rosenberg SA, Kusugamik, Kawase T, et al. The development of new immunotherapies for the treatment of cancer using interleukin-2. Ann Surg 1990; 208:121.

FULL TEXT LINK

More>

Views

343

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

The treatment of non-small cell lung cancer by interstitial I-125 seeds implantation combined with chemotherapy and Chinese medicine

Yiqi Zhuyu Decoction (益气逐瘀汤) Combined with FOLFOX-4 as first-line therapy in metastatic colorectal cancer

In Vitro and In Vivo inhibitory effect of the combination of Wenxia Changfu Formula (温下肠腑方) with cisplatin in non-small cell lung cancer

Clinical observation on treatment of colonic cancer with combined treatment of chemotherapy and Chinese herbal medicine

Clinical observation on chemical damage of nephron and the preventive and therapeutic effects of Baoshen Mixture (保肾合剂) on it

Related Author

No data

Related Institution

Department of Radiology, Chinese People’s Liberation Army General Hospital

Department of Traditional Chinese Medicine, Chinese People’s Liberation Army General Hospital

Department of Colorectal Surgery, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Colorectal Cancer Center of Shanghai Jiaotong University

Department of Colorectal and Anal Surgery, the First Affiliated Hospital of Guiyang College of Traditional Chinese Medicine

School of Basic Medical Science, Shandong University of Traditional Chinese Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰